Innovations in Care...
...Improvements in
Lives
...Improvements in
Lives...Improvements in
Lives 
Home • About Us •
Gamma Detection Devices
• Blood
Flow Measurement • Investigational
Initiatives • News
& Investors • Contact
Us • Site
Map
|
|
|||
 |
|
|
||
 |
|
|||
| RIGS®
(Caution –Investigational Product) The RIGS system combines a patented hand-held gamma radiation detection probe, proprietary radiolabeled cancer-specific targeting agents, and patented surgical methods to provide surgeons with real-time information to locate tumor deposits not detectable by conventional methods, and to assist in more thorough removal of the cancer. The RIGS system is designed to assist the surgeon in the more thorough removal of the cancer, thereby leading to improved surgical treatment of the patient. The targeting agents used in the RIGS process are monoclonal antibodies, labeled with a radioactive isotope that emits low energy gamma rays. The device used is a very sensitive radiation detection instrument that is capable of detecting small amounts of radiation bound to the targeting agent. Before surgery, a cancer patient is injected with one of the targeting agents which circulates throughout the patient’s body and binds specifically to cancer cell antigens or receptors. Concentrations of the targeting agent are then located during surgery by Neoprobe's gamma-detection device, which emits an audible tone to direct the surgeon to targeted tissue. Information on the clinical history and current development status of RIGS can be obtained from Neoprobe’s recent press releases and filings with the U.S. Securities and Exchange Commission. The links below also provide further information about the RIGS system. 2. Staging of Colorectal Cancer: Biology vs. Morphology |
|
|||
| |
||||
| Copyright © Neoprobe Corporation. All rights reserved. Your use of the information on this site is subject to our terms of use. | |
|||
